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Abstract
Aim This study aimed at evaluating the cost-effectiveness of different non-invasive imaging-guided strategies for the diag-
nosis of obstructive coronary artery disease (CAD) in a European population of patients from the Evaluation of Integrated 
Cardiac Imaging in Ischemic Heart Disease (EVINCI) study.
Methods and results Cost-effectiveness analysis was performed in 350 patients (209 males, mean age 59 ± 9 years) with 
symptoms of suspected stable CAD undergoing computed tomography coronary angiography (CTCA) and at least one cardiac 
imaging stress-test prior to invasive coronary angiography (ICA) and in whom imaging exams were analysed at dedicated core 
laboratories. Stand-alone stress-tests or combined non-invasive strategies, when the first exam was uncertain, were compared. 
The diagnostic end-point was obstructive CAD defined as > 50% stenosis at quantitative ICA in the left main or at least one 
major coronary vessel. Effectiveness was defined as the percentage of correct diagnosis (cd) and costs were calculated using 
country-specific reimbursements. Incremental cost-effectiveness ratios (ICERs) were obtained using per-patient data and 
considering “no-imaging” as reference. The overall prevalence of obstructive CAD was 28%. Strategies combining CTCA 
followed by stress ECHO, SPECT, PET, or stress CMR followed by CTCA, were all cost-effective. ICERs values indicated 
cost saving from − 969€/cd for CMR-CTCA to − 1490€/cd for CTCA-PET, − 3092€/cd for CTCA-SPECT and − 3776€/cd 
for CTCA-ECHO. Similarly when considering early revascularization as effectiveness measure.
Conclusion In patients with suspected stable CAD and low prevalence of disease, combined non-invasive strategies with 
CTCA and stress-imaging are cost-effective as gatekeepers to ICA and to select candidates for early revascularization.
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Invasive coronary angiography · Stress-imaging
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Introduction
Currently, available guidelines for symptomatic patients 
with suspected stable coronary artery disease (CAD) rec-
ommend diagnostic flow-charts using computed tomography 
coronary angiography (CTCA) as the first-line investigation 
in all patients [1] or stress imaging and CTCA according to 
the pre-test probability (PTP) [2]. Additional non-invasive 
testing is also considered in the case of uncertain results of 
the first test [1, 2].
Despite this and in view of the wide range of valid avail-
able options, the selection of non-invasive imaging in clini-
cal practice may be influenced by factors not included in 
guidelines [2]. Moreover, direct referral to invasive coronary 
angiography (ICA) is not uncommon and may result in a 
relatively high percentage of negative exams thus inducing 
potentially avoidable costs [3].
While innovations in medical imaging have brought 
unquestionable benefits improving diagnostic and prognostic 
accuracy of non-invasive pathways, that success is counter-
balanced by an escalation of imaging costs. Evidence sug-
gests that the cost of diagnostic imaging has nearly doubled 
in the past few decades and there is also a wide variation 
among countries, due to different practice, healthcare and 
reimbursement systems [4, 5]; thus the rapid spread of car-
diovascular disease in Europe and in fact worldwide, com-
bined with the increasing use of testing via non-invasive 
approaches, suggest the need for guidance in appropriate 
decision making.
Accordingly, studies reporting results about cost-effec-
tiveness evaluation of strategies for CAD have slightly 
increased over the years [6].
In detail, as for clinical studies [7], available economic 
evaluations of diagnostic strategies for CAD have varied 
widely regarding the alternatives compared and the method-
ological approaches used [6]; moreover, the different nature 
and organization of healthcare systems worldwide and vari-
ability of cost over different contexts strongly affect results 
from economic evaluations. Thus, if clinical research has 
provided consistent evidence encouraging the use of both 
CTA and functional tests in the diagnostic pathway [7], the 
economic perspective is still an open challenge.
In detail, currently available economic studies frequently 
fail to map all possible options that became available for 
the diagnosis of stable CAD; many of them use different 
reference strategies (i.e., primarily ICA and CTCA) and 
indeed most studies focused on the comparison of a single 
test failing to produce evidence on a combination of differ-
ent options; contrary to the direction in which the results 
of the clinical studies are going. As recent reviews of eco-
nomic studies highlighted, results from available economic 
evaluations of non-invasive imaging strategy for stable CAD 
remains controversial, with no modality consistently emerg-
ing as superior to all others and across all patient subgroups 
[7, 8] and thus not useful to orient clinical practice.
The Evaluation of Integrated Cardiac Imaging for 
the Detection and Characterization of Ischemic Heart 
Disease (EVINCI) study (ClinicalTrials.gov Identifier: 
NCT00979199) was a multicenter, multinational European, 
non-randomized controlled clinical trial intended to compare 
the performance of CTCA and available non-invasive stress-
imaging modalities for the diagnosis of obstructive CAD in 
patients with stable chest pain symptoms, intermediate PTP 
and without prior evidence of disease. The main results of 
the EVINCI study have been reported elsewhere [9].
The health economic analysis was a major secondary aim 
of the study, and the EVINCI design allowed comparing 
strategies involving single modalities or combinations of 
CTCA and stress imaging for diagnostic cost-effectiveness 
with the potential of providing valuable evidence and resolv-
ing some limitations of available evidence, first and foremost 
with respect to the evaluation of strategies combining imag-
ing modalities.
Materials and methods
Study population and data
Per-patient data from the EVINCI study were used in the 
present analysis. Briefly, the EVINCI trial prospectively 
enrolled patients with symptoms of suspected stable CAD, 
without prior evidence of disease and intermediate PTP, 
after exclusion of those subjects reclassified to very low or 
high risk after performing an exercise ECG [9]. The study 
was performed in 13 centers from eight different European 
countries. By protocol, patients underwent CTCA and at 
least one imaging stress-test from among cardiac magnetic 
resonance (CMR), echocardiography (ECHO) positron 
emission tomography (PET) or single photon computed 
emission tomography (SPECT). All patients with at least 
one positive non-invasive exam were referred to ICA. Stand-
ard acquisition and analysis protocols were agreed on for 
each technique, image quality analysis and reporting was 
performed independently at each recruiting center and at 
dedicated core-laboratories (where observers were blinded 
to the clinical data and to any other test results). Among the 
697 patients initially enrolled, 475 patients completed the 
entire protocol. To ensure homogeneous evaluation of imag-
ing tests, only data from the 350 patients who had complete 
core-laboratory evaluation were used in the present analysis. 
Analyses were repeated in the subgroup of patients (N = 101) 
having complete data on ICA, CTCA, and both ECHO and 
SPECT, the most frequently used imaging stress tests.
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Diagnostic strategies
Thirteen strategies involving CTCA and single imaging stress-
tests or their combinations were evaluated. Positivity criteria 
and quality evaluation at core-lab analysis for each non-inva-
sive test were detailed in Neglia et al. [9]. Any test was defined 
as uncertain by core-labs if the image quality was judged as 
suboptimal. Stress tests were also defined as uncertain if they 
did not show abnormalities but the stress protocols were inad-
equate (submaximal stress, therapy not withdrawn). Accord-
ing to Guidelines [2], combined strategies were built with 
CTCA as the first test followed by one stress-imaging in case 
of uncertain CTCA results or with one stress-imaging as first 
test followed by CTCA in case of uncertain stress-test results. 
For the cost-effectiveness analysis each strategy was defined 
as positive or negative as schematically shown in Fig. 1.
Obstructive CAD was defined as > 50% diameter steno-
sis in the left main or at least one major coronary vessel by 
quantitative ICA at core-lab analysis. For all imaging-guided 
diagnostic strategies true positives (TP) or true negatives 
(TN) (correct diagnoses) were defined in concordance with 
ICA results. In patients who did not perform invasive evalu-
ation due to all negative non-invasive exams, and in whom 
negativity was confirmed by core-labs, all strategies were 
assumed to be true negatives. For the cost-effectiveness 
analysis, a “no-imaging” strategy was taken as reference 
and direct referral to ICA was considered as a comparative 
pathway. The “no-imaging” strategy was assumed to provide 
a correct diagnosis only in patients with negative ICA, while 
the direct invasive strategy was assumed to provide a correct 
diagnosis in all patients.
Definition of effectiveness and costs
Effectiveness was defined in terms of correct diagnosis. For 
each patient and for each strategy, a dichotomous variable of 
effectiveness was defined taking the value of “one” in case 
of concordance with ICA results and the value of “zero” in 
case of discordance.
Country-specific charge collected through the EVINCI 
study was used to quantify costs associated with single tests 
and combinations. In particular, in each participating center, 
clinicians and administrative personnel filled a dedicated case 
report form including code, description, charge and reimburse-
ment regimen for different tests. Collected data were checked 
against national administrative data, when available, and 
inconsistencies were solved by direct contacts with the center. 
Overall costs of the different strategies were thus estimated 
for each patient adding the specific cost data to costs associ-
ated with false negative or false positive results. In published 
reports [10–13], the cost of a false negative imaging test has 
been variably estimated as being 2–6 times the cost of ICA, on 
the assumption that it could lead to additional testing later on. 
In the present study, using a conservative approach, the cost 
of a false negative strategy was assumed to be twice the cost 
of ICA. The cost of a false positive strategy was assumed to be 
the cost of an unnecessary ICA. In the case of the “no-imag-
ing” strategy the cost was only related with false negatives. All 
Fig. 1  Each single or combined 
imaging strategy was defined 
as positive or negative as sche-
matically shown SINGLE TEST 
CTCA or  
Stress Imaging
Negative 
Positive 
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CTCA or  
Stress Imaging
Uncertain
Uncertain or 
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SECOND TEST 
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costs were converted to Euro 2012 using the official exchange 
rate [14] and then adjusted by the purchasing power parity 
(PPP) [15] to account for differences in the opportunity cost 
of resources across the economies considered [16].
Cost‑effectiveness analysis
The cost-effectiveness analysis was performed using the 
payer perspective and the diagnostic performance as meas-
ure of effectiveness. Using the “no-imaging” strategy as ref-
erence, the cost-effectiveness ratio (ICER) was defined as 
incremental cost for one more correct diagnosis (€/cd) over 
100 patients. Mean costs, effectiveness and the cost-effec-
tiveness ratios (CERs) were derived for all the strategies. 
Strategies were then ranked based on ascendant order of 
costs and effectiveness. The ICERs were thus derived as the 
ratio of incremental costs by incremental unit of effective-
ness after excluding strategies “dominated” (less effective 
and more costly than one or more strategies) or subjected 
to “extended dominance” (dominated by a linear combina-
tion of other strategies). The 95% confidence intervals for 
ICER were computed by means of non-parametric bootstrap 
with 10,000 replicates and accounting for the hierarchical 
structure of the data, with patients clustered into countries.
Scenario analysis
In a scenario analysis, concordance of positive/negative 
non-invasive strategies results with performed/not-per-
formed early revascularization procedures (within 90 days 
from enrolment based on independent clinical decision of 
the local attending physicians) was used as an alternative 
measure of effectiveness.
Sub‑group analysis
Both the main analysis and the scenario analysis were 
repeated in the subgroup of the EVINCI population in which 
each patient had undergone CTCA, stress ECHO, stress 
SPECT and ICA.
The main cost-effectiveness analysis was also performed 
separately in the different countries.
Results
Details of patients’ characteristics, diagnostic performance 
of single tests and combined non-invasive strategies as 
well as costs are available as Supplementary data (Tables 
S1–S3). Briefly, demographics and clinical characteristics 
of patients undergoing each different imaging were fairly 
well matched, with patients undergoing PET being less 
likely males with lower prevalence of family history of 
CAD and less typical symptoms. The overall prevalence of 
obstructive CAD was 28% and was similar among groups 
(Table S1).
The diagnostic performance, as expressed by the per-
centage of correct diagnoses (TP + TN), was in general 
higher for combined CTCA and stress imaging strategies 
than for single non-invasive tests (Table S2).
Country-specific reimbursement for the different non-
invasive tests and ICA largely varied across countries and 
variability remained substantial also when adjusting for 
PPP (Table S3).
Cost‑effectiveness analysis
Results of the main cost-effectiveness analysis for the 
diagnosis of obstructive CAD are summarized in Table 1. 
Mean costs and effectiveness over 100 patients are 
reported for each strategy together with delta costs, delta 
effectiveness and ICERs obtained via bootstrap replicates 
using “no-imaging” as reference. Strategies using stand-
alone CTCA, a specific stress-test, their combinations 
(CTCA first or stress-test first) or direct referral to ICA 
are compared. Combined non-invasive strategies including 
CMR-CTCA, CTCA-ECHO, CTCA-PET, CTCA-SPECT 
and direct referral to ICA were all cost-effective and domi-
nated stand-alone stress-imaging or the other combina-
tions. Stand-alone CTCA had lower induced costs, but 
only a marginal improvement in effectiveness as compared 
with “no-imaging”. Cost savings per one additional cor-
rect diagnosis over 100 patients ranged from 969 €/cd for 
CMR-CTCA to 1490 €/cd for CTCA-PET, 3092 €/cd for 
CTCA-SPECT and 3776€/cd for CTCA-ECHO. Direct 
referral to ICA was cost-effective but with additional costs.
The differences in mean cost and in mean effective-
ness (with relative contour plots representing confidence 
intervals of the distribution generated from bootstrap 
analysis) are shown in Fig. 2. The distribution plot for 
ICA is located in the upper right quadrant, thus indicat-
ing higher effectiveness at the price of higher costs. The 
distribution plot for stress ECHO is located in the lower 
left quadrant demonstrating not only reduction of costs 
but also lower diagnostic effectiveness, while uncertainty 
exists for all other self-standing tests. For combined strate-
gies, the distribution plots for CMR-CTCA, CTCA-ECHO, 
CTCA-PET and CTCA-SPECT are consistently located in 
the lower right quadrants, indicating gain in effectiveness 
with reduced costs, with some uncertainty in particular 
for CMR-CTCA.
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When considering early revascularization as an alter-
native measure of effectiveness, combined strategies with 
CTCA as gatekeeper followed by either stress CMR, ECHO, 
PET or SPECT were all cost-effective as compared with 
“no-imaging” and dominated stand-alone or other combined 
strategies, despite some uncertainty around the point esti-
mate of the ICERs. Direct referral to ICA was cost-effective 
requiring additional costs (Table 2).
Subgroup analysis
The main results of the cost-effectiveness analysis were con-
firmed in the subgroup of 101 patients submitted to CTCA, 
stress ECHO, stress SPECT and ICA (Table 3). Combined 
CTCA-ECHO and CTCA-SPECT strategies were cost-
effective for the diagnosis of obstructive CAD dominating 
stand-alone stress-tests and other combinations. Stand-alone 
CTCA was also cost-effective but provided slightly lower 
diagnostic accuracy than combined strategies. Direct refer-
ral to ICA was cost-effective with higher costs per correct 
diagnosis. Considering early revascularization as alterna-
tive measure of effectiveness, only CTCA-SPECT [ICER 
− 9520€/cd (95% CI: − 26,872 to − 18,200)] was a cost-
effective non-invasive strategy while direct referral to ICA 
[ICER: 7064€/cd (95% CI: 2214–57,913)] was cost-effective 
but required additional costs (Table 4).
Results from the country-specific cost-effectiveness 
analysis indicated high variability among countries and 
Table 1  Results of the cost-
effectiveness analysis of single 
or combined imaging strategies 
for the diagnosis of obstructive 
CAD
Mean costs and effectiveness over 100 patients are reported together with delta costs, delta effectiveness 
and ICERs obtained via bootstrap replicates using “no imaging” strategy as reference. Strategies involving 
CTCA, each stress imaging modality and combinations or direct referral to ICA are compared and listed in 
order of increasing costs
cd correct diagnosis, CMR cardiac magnetic resonance, CTCA computed-tomography-coronary-angiogra-
phy, ECHO stress-echocardiography, ICA invasive-coronary-angiography, ICER incremental-cost-effective-
ness-ratio, PET positron-emission-tomography, SPECT single-photon-emission-computed-tomography
Cost, € Effective-
ness, %
Δ Cost Δ Effectiveness ICER (95% CI)
CMR
 No-imaging 98,991 72 – – –
 CTCA 51,205 73 − 47,811 0.6 − 79,685 (− 153,074; 144,834)
 CMR 84,388 80 − 14,763 8.5 Extended dominated
 CTCA-CMR 87,203 77 − 11,985 4.9 Dominated
 CMR-CTCA 87,209 84 − 11,819 12.2 − 969 (− 2282; 7001)
 ICA 165,111 100 66,151 28 2362 (1495; 3504)
ECHO
 No-imaging 98,991 72 – – –
 ECHO 42,612 55 − 56,414 − 17 Extended dominated
 CTCA 51,205 73 − 47,811 0.6 Extended dominated
 CTCA-ECHO 51,216 85 − 47,886 12.7 − 3776 (− 6177; − 2740)
 ECHO-CTCA 58,781 80 − 40,407 8 Dominated
 ICA 165,111 100 66,151 28 2362 (1495; 3504)
PET
 No-imaging 98,991 72 – – –
 CTCA 51,205 73 − 47,811 0.6 − 79,685 (− 153,074; 144,834)
 CTCA-PET 79,901 85 − 19,073 12.8 − 1490 (− 3185; 1393)
 PET 117,722 71 18,663 − 0.8 Dominated
 PET-CTCA 134,117 76 35,232 4.2 Dominated
 ICA 165,111 100 66,151 28 2362 (1495; 3504)
SPECT
 No-imaging 98,991 72 – – –
 CTCA 51,205 73 − 47,811 0.6 − 79,685 (− 153,074; 144,834)
 CTCA-SPECT 74,635 80 − 24,425 7.9 − 3092 (− 7998; − 504)
 SPECT 90,125 68 − 9035 − 4.2 Dominated
 SPECT-CTCA 103,446 77 4260 4.8 Dominated
 ICA 165,111 100 66,151 28 2362 (1495; 3504)
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high uncertainty for most of the strategies, mainly due to the 
limited sample size (Figs. 3, 4 and 5). However, combined 
strategies improved effectiveness of stand-alone stress-tests 
or CTCA with few exceptions, while the impact on costs was 
variable depending on the rate of false test results and on the 
local costs of the various tests.
Discussion
The economic evaluation of the EVINCI study indicates 
that non-invasive strategies combining CTCA with stress-
imaging, in the case of inconclusive results of the first test, 
are cost-effective diagnostic options in patients with stable 
chest pain symptoms and low prevalence of obstructive 
CAD. CTCA as first test followed by stress ECHO, SPECT, 
PET or stress CMR as first test followed by CTCA were 
associated with overall reduced costs and higher diagnostic 
efficacy, as compared with a “no-imaging” strategy, self-
standing single non-invasive tests or other combinations. 
Direct referral to ICA was also a cost-effective option but 
required additional costs. In general, whether the com-
bination of CTCA with stress-imaging would be used as 
gate-keeper to catheterization, the positive yield of ICA for 
the diagnosis of obstructive CAD would increase from 28 to 
47% and the rate of revascularizations performed from 19% 
up to 40% (Fig. 6).
What is new for self‑standing vs combined 
non‑invasive imaging diagnostic strategies
In detail, the present study highlights the lower perfor-
mance of self-standing non-invasive imaging modalities 
as compared with combined strategies and that could be 
explained by multiple factors. The EVINCI population, 
as most recent cohorts enrolled in imaging trials [17, 18], 
had a low prevalence of obstructive CAD (28%). In this 
low-risk populations, it is expected that the prevalence 
of extensive disease, able to induce severe ischemia and 
contractile impairment, is even lower. Thus strategies 
using self-standing wall motion-based imaging, in particu-
lar stress ECHO, are expected to reduce overall costs by 
reducing the number of ICA exams but will be associated 
with more false negatives, i.e., unrecognized obstructive 
CAD. Conversely, perfusion-based stress imaging strat-
egies are expected to have more false positive results 
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Fig. 2  Differences in mean cost and in mean effectiveness (with rela-
tive contour plots representing confidence intervals obtained from 
bootstrap analysis) are plotted in four different cost-effectiveness 
planes allowing comparison of self-standing CTCA, one stress-imag-
ing and their combinations
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driving the additional costs of more unusual ICA. As a 
matter of fact, in the EVINCI study false positives ranged 
from 0 to 2.1% for stress CMR and ECHO, to 6.4–13.6% 
for stress SPECT and PET and false negatives from 
13.4–8.5% to 9.1–3.4%, respectively (Table 2). CTCA 
had fewer false positives than SPECT and PET and fewer 
false negatives than CMR and ECHO. Moreover, in these 
“real world” populations, each modality is frequently not 
exploited at its full potential and a substantial percentage 
of imaging tests may be inconclusive, as demonstrated by 
the core-lab analysis of the EVINCI data. Thus, combining 
CTCA with stress-imaging may reduce uncertain results 
and improve the diagnostic performance of the combined 
strategies, thus ultimately reducing the overall costs per 
correct diagnosis.
The present findings cannot be extended to popula-
tions with higher prevalence of disease and do not provide 
information on the impact on long-term clinical outcome. 
However, from a health economic perspective they support 
the diagnostic use of integrated non-invasive imaging for 
the screening of patients with suspected stable CAD rec-
ommended in the 2013 ESC Guidelines [2] and the role of 
CTCA was recently underlined by the UK National Institute 
for Health and Clinical Excellence [1].
Table 2  Results of the cost-
effectiveness analysis of 
single or combined imaging 
strategies when concordance 
of imaging results with early 
revascularization performed 
was taken as measure of 
effectiveness
Mean costs and effectiveness over 100 patients are reported together with delta costs, delta effectiveness 
and ICERs obtained via bootstrap replicates using “no imaging” strategy as reference. Strategies involving 
CTCA, each stress imaging modality and combinations or direct referral to ICA are compared and listed in 
order of increasing costs
cd correct diagnosis, CMR cardiac magnetic resonance, CTCA computed-tomography-coronary-angiogra-
phy, ECHO stress-echocardiography, ICA invasive-coronary-angiography, ICER incremental-cost-effective-
ness-ratio, PET positron-emission-tomography, SPECT single-photon-emission-computed-tomography
Cost, € Effective-
ness, %
Δ Cost Δ Effectiveness ICER (95% CI)
CMR
 No-imaging 86,694 76 – – –
 CTCA-CMR 76,200 82 − 10,735 5.9 − 1820 (− 13,138; 10,446)
 CTCA 84,369 69 − 2336 − 6.8 Dominated
 CMR-CTCA 93,814 81 7135 4.5 Dominated
 CMR 96,873 77 9828 0.8 Dominated
 ICA 183,268 90 96,518 14.0 6876 (4017; 13,483)
ECHO
 No-imaging 86,694 76 – – –
 CTCA-ECHO 70,431 78 − 16,300 1.8 − 9312 (− 43,091; 40,926)
 ECHO-CTCA 79,122 74 − 7692 − 2.4 Dominated
 CTCA 84,369 69 − 2336 − 6.8 Dominated
 ECHO 101,899 50 15,073 − 26.2 Dominated
 ICA 183,268 90 96,518 14.0 6876 (4017; 13,483)
PET
 No-imaging 86,694 76 – – –
 CTCA 84,369 69 − 2336 − 6.8 Dominated
 CTCA-PET 87,652 80 754 4.3 177 (− 17,104; 16,468)
 PET 128,289 67 41,645 − 9.7 Dominated
 PET-CTCA 130,037 75 43,507 − 1.8 Dominated
 ICA 183,268 90 96,518 14.0 6876 (4017; 13,483)
SPECT
 No-imaging 86,694 76 – – –
 CTCA-SPECT 83,889 79 − 2683 2.3 1167 (− 21,796; 18,493)
 CTCA 84,369 69 − 2336 − 6.8 Dominated
 SPECT-CTCA 109,236 74 22,407 − 2.2 Dominated
 SPECT 112,447 66 25,491 − 9.4 Dominated
 ICA 183,268 90 96,518 14.0 6876 (4017; 13,483)
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Table 3  Results of the cost-
effectiveness analysis of 
different single or combined 
imaging strategies for (a) 
the diagnosis of obstructive 
CAD performed and (b) early 
revascularization in a subgroup 
of 101 patients
Mean costs and effectiveness over 100 patients are reported together with delta costs, delta effectiveness 
and ICERs obtained via bootstrap replicates using “no imaging” strategy as reference. Strategies involving 
CTCA, each stress imaging modality and combinations or direct referral to ICA are compared and listed in 
order of increasing costs
cd correct diagnosis, CTCA computed-tomography-coronary-angiography, ECHO stress-echocardiography, 
ICA invasive-coronary-angiography, ICER incremental-cost-effectiveness-ratio, SPECT single-photon-
emission-computed-tomography
Cost, € Correct 
diagnosis
Δ Cost, € Δ Effective-
ness, cd
ICER (95% CI), €/cd
(a)
 No-imaging 120,649 68 – – –
 CTCA 29,157 82 − 91,273 13.9 − 6566 (− 30,492; − 4284)
 CTCA-ECHO 37,462 84 − 83,296 15.9 − 5239 (− 12,176; − 3662)
 CTCA-SPECT 46,113 86 − 74,552 17.8 − 4188 (− 7195; − 3068)
 ECHO 47,824 48 − 72,940 − 20.8 Dominated
 ECHO-CTCA 62,699 78 − 57,989 9.8 Dominated
 SPECT 85,583 61 − 35,087 − 6.8 Dominated
 SPECT-CTCA 90,803 76 − 29,947 8 Dominated
 ICA 159,946 100 39,373 31.6 1246 (87; 3223)
(b)
 No-imaging 95,408 76 – – –
 CTCA 41,756 73 − 53,724 − 3.1 Extended dominated
 ECHO 48,021 40 − 47,176 − 35.9 Dominated
 CTCA-ECHO 50,485 75 − 45,047 − 1 Extended dominated
 CTCA-SPECT 65,082 79 − 30,351 3.2 − 9520 (− 26,872; 18,200)
 ECHO-CTCA 77,107 68 − 18,546 − 7.3 Dominated
 SPECT 86,313 59 − 9270 − 16.8 Dominated
 SPECT-CTCA 91,506 73 − 3692 − 3.2 Dominated
 ICA 184,442 88 89,013 13.6 7064 (2214; 57,913)
Table 4  Results of the 
effectiveness analysis of 
different single or combined 
imaging strategies for early 
revascularization in a subgroup 
of 101 patients
Mean costs and effectiveness over 100 patients are reported together with delta costs, delta effectiveness 
and ICERs obtained via bootstrap replicates using “no imaging” strategy as reference. Strategies involving 
CTCA, each stress imaging modality and combinations or direct referral to ICA are compared and listed in 
order of increasing costs
cd correct diagnosis, CTCA computed-tomography-coronary-angiography, ECHO stress-echocardiography, 
ICA invasive-coronary-angiography, ICER incremental-cost-effectiveness-ratio, SPECT single-photon-
emission-computed-tomography
Cost, € Correct 
prediction
Δ Cost, € Δ Effective-
ness, cd
ICER (95% CI), €/cd
No-imaging 95,408 76 – – –
CTCA 41,756 73 − 53,724 − 3.1 Extended dominated
ECHO 48,021 40 − 47,176 − 35.9 Dominated
CTCA-ECHO 50,485 75 − 45,047 − 1 Extended dominated
CTCA-SPECT 65,082 79 − 30,351 3.2 − 9520 (− 26,872; 18,200)
ECHO-CTCA 77,107 68 − 18,546 − 7.3 Dominated
SPECT 86,313 59 − 9270 − 16.8 Dominated
SPECT-CTCA 91,506 73 − 3692 − 3.2 Dominated
ICA 184,442 88 89,013 13.6 7064 (2214; 57,913)
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Fig. 3  Differences in mean cost and in mean effectiveness (with relative contour plots representing confidence intervals obtained from bootstrap 
analysis) are plotted in cost-effectiveness planes allowing comparison of self-standing CTCA, CMR and their combinations in different countries
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Fig. 4  Differences in mean cost and in mean effectiveness (with rela-
tive contour plots representing confidence intervals obtained from 
bootstrap analysis) are plotted in cost-effectiveness planes allowing 
comparison of self-standing CTCA, ECHO and their combinations in 
different countries
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Findings from the EVINCI cost‑effectiveness analysis 
and available evidence
Variability in the study design, imaging methods and meas-
ures of effectiveness and costs prevents an easy comparison 
of available studies with the present findings. Many exist-
ing studies were performed in selected populations recruited 
in single or a few expert centers in one nation and did not 
include all available modalities and combinations. In the 
CE-MARC study, for example, multi-parametric CMR per-
formed in a single expert center was compared with conven-
tional stress SPECT showing the superiority of strategies 
including CMR at cost-effectiveness analysis [19] as also 
documented in other nation-wide studies [20]. The CE-
MARC two-trial, performed in a larger population and in 
multiple centers, could not confirm significant differences 
between CMR and SPECT [21]. Similarly, in a large pro-
spective study there were no significant differences among 
stress CMR, ECHO or SPECT strategies in terms of effec-
tiveness or costs [22]. When CTCA and stress-imaging were 
compared [23, 24] over long-term follow-up, cost differences 
were minimal without significant differences in patient out-
come. Other recent cost-effectiveness analyses based on 
simulation models using available published data and lim-
iting the diagnostic evaluation to single tests followed by 
ICA for equivocal or abnormal results, suggested that direct 
referral to ICA for patients with low/intermediate probabil-
ity of CAD was not cost-effective [25]. In another recent 
study where diagnostic outcomes were modelled including 
imaging-guided treatments, lifetime prognosis was derived 
using a state-transition model, the results suggested that for 
patients with stable chest pain and a low/intermediate prob-
ability of CAD, CTCA as a triage test followed by cardiac 
stress imaging was cost effective [26].
Pragmatic randomized controlled trials (RCTs) are ben-
eficial in that they allow follow-up testing and care patterns 
to occur based on the patient’s overseeing physician and not 
constrained by trial-directed follow-up care, thereby reflect-
ing current real-world practices. However, they are also lim-
ited by possible inconsistency of patients’ management with 
imaging results and by variability in the outcome measure-
ments. The PROMISE study was the largest recent prag-
matic randomized controlled trial randomizing symptomatic 
patients without known CAD to CTCA or functional testing 
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Fig. 5  Differences in mean cost and in mean effectiveness (with rela-
tive contour plots representing confidence intervals obtained from 
bootstrap analysis) are plotted in cost-effectiveness planes allowing 
comparison of self-standing CTCA, SPECT and their combinations 
in different countries
Fig. 6  The diagnostic and therapeutic yield of invasive angiography, 
if indicated on the basis of non-invasive imaging strategies (without 
distinction among stress modalities) involving CTCA, Stress tests or 
combination of in different order (CTCA > stress and stress > CTCA). 
For comparison, the same figures are obtained when all patients 
would are referred directly to ICA
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including stress SPECT, ECHO or ECG [17]. The overall 
prevalence of obstructive CAD requiring revascularization 
was even lower than in the EVINCI study (< 5%). Within 
90 days of randomization, more patients in the CTCA arm 
underwent ICA, which showed more frequently obstructive 
CAD leading to more frequent revascularizations than in 
the functional testing arm. These differences, however, did 
not translate into superior outcomes at 25-month follow-
up either for the primary composite end-point or second-
ary end-points. Quality of life and symptoms were simi-
larly improved by both strategies and the economic analysis 
showed that CTCA and functional diagnostic testing strat-
egies had similar costs through 3 years of follow-up [23, 
27], but a lifetime cost-effectiveness analysis was not per-
formed because the hypothesized primary clinical benefits 
for CTCA were not found.
In the SCOT-HEART, patients were randomized to stand-
ard stress testing, including stress SPECT in a minority, or 
standard stress testing with a CTCA-guided strategy [18]. 
There was no difference in the number of downstream inva-
sive exams but, in the CTCA arm, ICA was more likely 
to show obstructive CAD and there was a trend for more 
early coronary revascularization procedures (< 90 days) 
with borderline significant reduction in the coronary event 
rates. In further analyses, the cumulative mean costs of treat-
ment over 6 months was higher in the CCTA group than for 
standard care alone, mainly attributable to the direct costs 
of CTCA itself, but a cost-effectiveness analysis was not 
performed [24].
In summary, in patients with suspected stable CAD and 
low-to-intermediate prevalence of obstructive disease, one 
modality or strategy did not consistently emerge as superior 
to all others from a health economics perspective [7, 28].
Despite the differences with other cost-effectiveness stud-
ies, the EVINCI analysis confirmed that no self-standing 
non-invasive imaging modality is superior to the others but 
also showed how strategies combining CTCA with stress-
imaging can be cost-effectively used to diagnose obstructive 
CAD and identify candidates to revascularization prior to 
ICA.
Improvement and strength of the EVINCI study 
over the state of the art
The present study improved the state of the art regarding the 
cost-effectiveness of strategies for the diagnosis of CAD, 
first of all by providing evidence in a contemporary Euro-
pean population with acceptable geographical and socio-
demographical “representativeness”, both updating evidence 
about self-standing non-invasive diagnostic strategies and 
also bringing data for the evaluation of combined strategies.
Finally, some other strengths of the EVINCI economic 
analysis are related to the process of gathering imaging 
data. These were prospectively obtained in a homogene-
ous European population of patients with symptoms of 
suspected stable CAD and low prevalence of disease, 
and head-to-head comparisons of multiple diagnostic 
strategies, including combinations, were allowed by the 
study protocol. Diagnostic effectiveness of tests was also 
objectively evaluated by independent core-labs and costs 
assessed in each center.
Limitations
One limitation of the present study regards the diverse utili-
zation of imaging modalities among the single countries and 
centers. Those differences, despite reflecting real-practice 
and the different spread of technologies among the involved 
centers, limited the direct comparison of all the strategies 
and of modalities exploited at their full potential. Similarly, 
this is so for the diverse number of patients assigned to the 
different strategies in different centers and countries. There 
were insufficient numbers to perform stratified analyses to 
account for these differences.
As the EVINCI study was designed for a diagnostic end-
point, correct diagnosis of obstructive CAD was used as 
measure of effectiveness. This implied the assumption of 
perfect accuracy of ICA, thus potentially giving CTCA an 
advantage over stress-imaging. On the other hand, in the 
scenario analysis based on the revascularizations performed, 
functional imaging was potentially advantaged.
Cost data collected throughout the EVINCI study showed 
high variability of charges for the different tests among the 
countries involved (Table S1). Despite this variability, ICA 
was always the most expensive procedure, while ECHO was 
the least expensive one, followed by CTCA. SPECT and 
CMR were generally more expensive than CTCA and asso-
ciated charges showed the highest variability, even when 
adjusted for PPP. As previously reported [8, 28, 29] such 
variability, beyond modelling approaches and assumptions, 
may have significantly impacted on results. As an additional 
limitation, the health economic evaluation was performed 
using charges and these often do not reflect real costs. To 
address some of these limitations, where possible, analy-
ses were performed considering recommendations for the 
analysis of multinational trials [30–32], thus using proper 
methods to adjust costs and to account for the hierarchi-
cal structure of the data and also providing country-specific 
results to overcome problems related to the transferability of 
results from the overall analysis. Further research is needed 
to define the possible determinants of this heterogeneity. 
Nevertheless, the present data may offer relevant informa-
tion to health-economists for conducting future studies as 
well as for interpreting the existing ones, in a multi-center 
and multi-national context.
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Conclusions
In a contemporary European population of patients with 
suspected stable CAD and low prevalence of disease, diag-
nostic strategies combining CTCA and stress-imaging are 
cost-effective as gatekeepers to ICA and for selecting can-
didates for revascularization. In a scenario of uncertainty 
about health economic consequences of multiple diagnostic 
pathways, a rational combination of non-invasive imaging 
modalities may offer the most cost- and clinically effective 
t!esting for the single patient.
The present results suggest the clinical and economic rel-
evance of improving the diagnostic performance of imaging 
tests and potentially limiting inconclusive imaging findings 
using more updated technologies, exploiting each tes!t at its 
full potential (i.e., combining perfusion and wall motion or 
anatomical and functional information) and strictly follow-
ing correct protocols. They also support the existing rec-
ommendations to clearly state when and why an imaging 
exam is inconclusive in the clinical reports [33] to indicate 
additional testing before referring the patient to invasive 
procedures.
Which imaging strategy, beyond its diagnostic perfor-
mance, is able to achieve the most important goal of effec-
tively guiding treatment to improve outcome in patients with 
stable CAD is still undetermined. Further large fully com-
parative multicenter, multinational, multimodality outcome-
based imaging trials are needed to provide useful global and 
country-specific health economic information.
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